JP2018529321A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529321A5
JP2018529321A5 JP2018506297A JP2018506297A JP2018529321A5 JP 2018529321 A5 JP2018529321 A5 JP 2018529321A5 JP 2018506297 A JP2018506297 A JP 2018506297A JP 2018506297 A JP2018506297 A JP 2018506297A JP 2018529321 A5 JP2018529321 A5 JP 2018529321A5
Authority
JP
Japan
Prior art keywords
protein
seq
amino acid
amino
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529321A (ja
JP7008014B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/001344 external-priority patent/WO2017025179A1/en
Publication of JP2018529321A publication Critical patent/JP2018529321A/ja
Publication of JP2018529321A5 publication Critical patent/JP2018529321A5/ja
Application granted granted Critical
Publication of JP7008014B2 publication Critical patent/JP7008014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506297A 2015-08-07 2016-08-04 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ Expired - Fee Related JP7008014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180278.2 2015-08-07
EP15180278 2015-08-07
PCT/EP2016/001344 WO2017025179A1 (en) 2015-08-07 2016-08-04 A transglutamine tag for efficient site-specific bioconjugation

Publications (3)

Publication Number Publication Date
JP2018529321A JP2018529321A (ja) 2018-10-11
JP2018529321A5 true JP2018529321A5 (enExample) 2019-09-12
JP7008014B2 JP7008014B2 (ja) 2022-02-10

Family

ID=53785570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506297A Expired - Fee Related JP7008014B2 (ja) 2015-08-07 2016-08-04 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ

Country Status (9)

Country Link
US (1) US11130818B2 (enExample)
EP (1) EP3331904B1 (enExample)
JP (1) JP7008014B2 (enExample)
CN (1) CN107922479A (enExample)
AU (1) AU2016306907A1 (enExample)
CA (1) CA2994741A1 (enExample)
ES (1) ES2855998T3 (enExample)
IL (1) IL256810B (enExample)
WO (1) WO2017025179A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP3272864A1 (en) * 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
HUE062089T2 (hu) * 2018-11-30 2023-09-28 Rao Naik Chetana Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások
CA3128571A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
PL3865155T3 (pl) 2020-02-13 2023-01-30 Orano Med Sposób miejscowo-specyficznego modyfikowania przeciwciała
CN116406302A (zh) 2020-09-18 2023-07-07 阿拉里斯生物技术股份公司 用基于氨基酸的接头的谷氨酰胺转胺酶缀合方法
PE20231512A1 (es) 2020-10-25 2023-09-26 Araris Biotech Ag Medios y metodos para producir conjugados de ligador-anticuerpo
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
JP2025506650A (ja) * 2022-02-17 2025-03-13 レボロ バイオセラピューティクス リミテッド シャペロニン60.1由来のペプチドを作製する方法
CN118742328A (zh) 2022-02-22 2024-10-01 阿拉里斯生物技术股份公司 包含两个或更多个有效载荷的肽接头
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
CN119744183A (zh) * 2023-07-31 2025-04-01 石药集团巨石生物制药有限公司 具有高药物负载的抗体-药物缀合物及其用途
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
BRPI0410863A (pt) * 2003-05-30 2006-07-04 Centocor Inc formação de novos conjugados de eritropoietina usando transglutaminase
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
EP3086813B9 (en) 2013-12-23 2023-09-27 Covalab Mtg substrates for covalent conjugation of compounds
NZ742916A (en) * 2015-12-18 2023-03-31 Eisai R&D Man Co Ltd C-terminal lysine conjugated immunoglobulins

Similar Documents

Publication Publication Date Title
JP2018529321A5 (enExample)
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
JP2019535315A5 (enExample)
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
IL261432B1 (en) Induced binding proteins and methods of use
JP2020517287A5 (enExample)
JP2020124209A5 (enExample)
JP2018033454A5 (enExample)
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
PE20211055A1 (es) Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
EA201691779A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CA3112310C (en) CHIMERIC ANTIGEN RECEPTOR GROUP (CAR)
AR066885A1 (es) Proteinas de fusion natriureticas
PE20212205A1 (es) Proteinas de union condicionalmente activadas restringidas
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
EA201200548A1 (ru) Биспецифические связывающие молекулы для антиангиогенезной терапии
JP2018537415A5 (enExample)
JP2018510864A5 (enExample)
JP2016519932A5 (enExample)
JP2016514463A5 (enExample)
JP2012025737A5 (enExample)
JP2012025766A5 (enExample)
WO2009007244A3 (en) Replication deficient influenza virus for the expression of heterologous sequences
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.